Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Contemporary Percutaneous Treatment of Infrapopliteal Arterial Disease: A Practical Approach

Contemporary Percutaneous Treatment of Infrapopliteal Arterial Disease: A Practical Approach Introduction Percutaneous treatment of peripheral arterial disease (PAD) has gained tremendous interest over the last few years. New devices and increasing operator experience has made percutaneous therapy first line therapy at many institutions. Infrapopliteal interventions are extremely rewarding because establishing straight line blood flow to the foot can provide adequate perfusion to heal ischemic ulcers and prevent amputation. With appropriate patient selection, acute procedural success and long‐term outcomes may be better than surgical bypass making percutaneous revascularization an important first treatment option at most institutions. Epidemiology The prevalence of PAD is estimated to be 27 million people in North America and Europe. The major risk factors for PAD are similar to those associated with atherosclerotic coronary artery disease (CAD), which include: advanced age, male sex, cigarette smoking, diabetes mellitus, hypertension and dyslipidemia. Cigarette smoking is a significant modifiable risk factor for CAD and PAD. More than 80% of the patients with PAD are either current or former smokers. The risk is correlated to the number of cigarettes smoked and is noted to be 2 to 3 times more in smokers than nonsmokers. Smoking is also 2 to 3 times more likely to cause lower extremity PAD than CAD. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Interventional Cardiology Wiley

Contemporary Percutaneous Treatment of Infrapopliteal Arterial Disease: A Practical Approach

Loading next page...
 
/lp/wiley/contemporary-percutaneous-treatment-of-infrapopliteal-arterial-disease-tps32dOg3I

References (58)

Publisher
Wiley
Copyright
Copyright © 2007 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0896-4327
eISSN
1540-8183
DOI
10.1111/j.1540-8183.2007.00264.x
pmid
17524115
Publisher site
See Article on Publisher Site

Abstract

Introduction Percutaneous treatment of peripheral arterial disease (PAD) has gained tremendous interest over the last few years. New devices and increasing operator experience has made percutaneous therapy first line therapy at many institutions. Infrapopliteal interventions are extremely rewarding because establishing straight line blood flow to the foot can provide adequate perfusion to heal ischemic ulcers and prevent amputation. With appropriate patient selection, acute procedural success and long‐term outcomes may be better than surgical bypass making percutaneous revascularization an important first treatment option at most institutions. Epidemiology The prevalence of PAD is estimated to be 27 million people in North America and Europe. The major risk factors for PAD are similar to those associated with atherosclerotic coronary artery disease (CAD), which include: advanced age, male sex, cigarette smoking, diabetes mellitus, hypertension and dyslipidemia. Cigarette smoking is a significant modifiable risk factor for CAD and PAD. More than 80% of the patients with PAD are either current or former smokers. The risk is correlated to the number of cigarettes smoked and is noted to be 2 to 3 times more in smokers than nonsmokers. Smoking is also 2 to 3 times more likely to cause lower extremity PAD than CAD.

Journal

Journal of Interventional CardiologyWiley

Published: Jun 1, 2007

There are no references for this article.